Notice ro Health Care Providers

The FDA has recently issued a Letter to Clinical Laboratory Staff and Health Care Providers to remind them about the possibility of false reactive results in herpes simplex virus type 2 (HSV-2) serological tests for genital herpes. Clinical diagnosis of genital herpes can be challenging, and the Centers for Disease Control and Prevention suggest that the likelihood of a false result increases when using current HSV tests, particularly if a person:

• gets a blood test too soon after infection
• has a low risk of infection
• receives test results that are near the cutoff (low positive)

Read More

Updated By Anita Johnson-Brown|The Los Angeles News

More News from Los Angeles

• News Mix Top News
• Anita Brown's commentary Opinions matter